Empagliflozin reduces the progression of hepatic fibrosis in a mouse model and inhibits the activation of hepatic stellate cells via the hippo signalling pathway

HIGHLIGHTS

• who: Yu-Jung Heo and collaborators from the Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea have published the Article: Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway, in the Journal: Biomedicines 2022, 1032 of 29/04/2022
• what: The authors demonstrated that EMPA attenuated CDAHFD-induced liver fibrosis in_vivo and inhibited HSC proliferation and activation in_vitro.
• how: The authors used male C57 BL/6 J mice fed a choline-deficient l-amino . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.